Cargando…
MiR‐3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway
Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma. Yet, resistance to TMZ is a chief hurdle towards curing the malignancy. The current work explores the pathways and involvement of miR‐3116 in the TMZ resistance. miR‐3116 and FG...
Autores principales: | Kong, Shiqi, Cao, Yingxiao, Li, Xin, Li, Zhenzhong, Xin, Yuling, Meng, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176860/ https://www.ncbi.nlm.nih.gov/pubmed/32181582 http://dx.doi.org/10.1111/jcmm.15133 |
Ejemplares similares
-
miR‐1254 inhibits progression of glioma in vivo and in vitro by targeting CSF‐1
por: Li, Xin, et al.
Publicado: (2020) -
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
por: Cao, Yingxiao, et al.
Publicado: (2020) -
Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019) -
MicroRNA-761 targets FGFR1 to suppress the malignancy of osteosarcoma by deactivating PI3K/Akt pathway
por: Lv, Zhongzhe, et al.
Publicado: (2019) -
Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)